Keep in mind that's for just $2MM, to keep the lights on. To do a trial, multiply those share issuance by 10. And that's if we were even granted the same terms. And the MFO could simply decline further amended deals, as Aspire did.
The MFO was likely reluctant to exercise more warrants (which entails paying for preferred shares, risking more capital) so we had to sweeten the deal. We let go the assistant clinical development director, which you don't do when a trial is definitely on the horizon.
Root for a deal :-) And ignore foolishness.
News 
Market Data 
Discover 
